Melanoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 102 expanded access programs, clinical trials, and compassionate use pathways listed for Melanoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with melanoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 29 programs are currently active or recruiting, with the remaining 73 in other lifecycle stages. Sponsors actively running programs in this area include Bristol-Myers Squibb, Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center, and others.
By recruiting status
Snapshot of where every Melanoma program currently sits in its lifecycle.
- Active / Recruiting29
- Inactive73
Top sponsors
Organisations running the most Melanoma programs in the directory.
- Bristol-Myers Squibb6 programs
- Regeneron Pharmaceuticals6 programs
- Merck Sharp & Dohme LLC5 programs
- H. Lee Moffitt Cancer Center and Research Institute4 programs
- M.D. Anderson Cancer Center4 programs
- Memorial Sloan Kettering Cancer Center3 programs
- National Cancer Institute (NCI)3 programs
- Novartis Pharmaceuticals3 programs
- Abramson Cancer Center at Penn Medicine2 programs
- Amgen2 programs
Melanoma programs (102)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Encorafenib, Binimetinib, and Pembrolizumab for Advanced or Metastatic Melanoma — Pfizer
- Study on the Safety and Effectiveness of REGN10597 for Adults with Advanced Solid Tumors — Regeneron Pharmaceuticals
- Phase 2 Trial for Metastatic Melanoma Using Cell Therapy with Tumor Infiltrating Lymphocytes and IL-2, with or without Pembrolizumab — National Cancer Institute (NCI)
- Phase II Study of Tocilizumab with Ipilimumab and Nivolumab for Advanced Melanoma — NYU Langone Health
- Study on Ceralasertib Alone and with Durvalumab for Melanoma Resistant to PD-(L)1 Treatment — AstraZeneca
- Study Comparing Relatlimab and Nivolumab Combination to Nivolumab Alone in Advanced Melanoma — Bristol-Myers Squibb
- Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Long-Term Health of Adults from a Previous Melanoma Treatment Study — Regeneron Pharmaceuticals
- Study on the Safety and Effectiveness of Fianlimab and Cemiplimab Compared to Pembrolizumab in Treating Resectable Stage 3 or 4 Melanoma — Regeneron Pharmaceuticals
- Study on Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma — Brown University
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Nivolumab vs. Placebo for Preventing Melanoma from Returning After Surgery — Bristol-Myers Squibb
- Study on ENB003 and Pembrolizumab for Treating Solid Tumors — ENB Therapeutics, Inc
- Study on Lymphodepletion and Cell Transfer with or without Dendritic Cell Immunization for Metastatic Melanoma — M.D. Anderson Cancer Center
- Study on Metronomic Cyclophosphamide and Pembrolizumab for Melanoma Resistant to Checkpoint Inhibitors — University of California, Irvine
- Study on Immunotherapy Before and After Surgery for Advanced Melanoma — H. Lee Moffitt Cancer Center and Research Institute
- Study on Ipilimumab and Nivolumab Before Surgery for Patients with Recurrent, High-Risk, Resectable Melanoma — University of Utah
- Study on Using Pembrolizumab Before Surgery for Stage IIB/C Melanoma — Abramson Cancer Center at Penn Medicine
- Study on Nivolumab/Ipilimumab and Cabozantinib for Patients with Advanced Melanoma That Cannot Be Surgically Removed — Georgetown University
- Study on Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Diwakar Davar
- Study on Pembrolizumab and Ipilimumab for Melanoma After Previous Immunotherapy — University of Chicago
- Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
- Phase I/II Study of CD40L-Enhanced TIL Therapy for Advanced Melanoma Patients — H. Lee Moffitt Cancer Center and Research Institute
- Study on Combining Radiation with Tarlatamab for DLL3 Expressing Tumors — University of Arizona
- Study on the Safety and Effectiveness of Pembrolizumab Compared to Placebo in Patients with High-Risk Stage II Melanoma — Merck Sharp & Dohme LLC
- Study on the Effectiveness and Safety of LXH254 Combinations in Patients with Previously Treated Advanced Melanoma — Novartis Pharmaceuticals
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on Treating Melanoma with ALK Alterations Using Ensartinib — Memorial Sloan Kettering Cancer Center
- Study on Intratumoral T3011 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — ImmVira Pharma Co. Ltd
- Study on V940 and Pembrolizumab for People with High-Risk Melanoma — Merck Sharp & Dohme LLC
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on BA3071 for Patients with Solid Tumors — BioAtla, Inc.
- Study on KSQ-001EX, a New Treatment Using Modified Immune Cells for Advanced Solid Tumors — M.D. Anderson Cancer Center
- Study on RP1 for Organ Transplant Patients with Advanced Skin Cancers — Replimune Inc.
- A Study on the Safety and Effectiveness of Vemurafenib and Metformin for Melanoma Patients — University of Louisville
- Study on APG-115 Alone or with Pembrolizumab for Patients with Metastatic Melanomas or Advanced Solid Tumors — Ascentage Pharma Group Inc.
- Study on BMS-986253 with Nivolumab or Nivolumab Plus Ipilimumab for Advanced Cancers — Bristol-Myers Squibb
- Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors — Bristol-Myers Squibb
- Study on Cobolimab and Dostarlimab for Children and Young Adults with Cancer — GlaxoSmithKline
- Study of Dapansutrile and Pembrolizumab for Advanced Melanoma Resistant to PD-1 Treatment — April Salama, M.D.
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on IBI363 for Patients with Advanced Solid Tumors — Innovent Biologics (Suzhou) Co. Ltd.
- Study on IO102/IO103, Nivolumab, and Relatlimab for People with Melanoma — Memorial Sloan Kettering Cancer Center
- Study on Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine for Advanced Melanoma — Ravi Amaravadi, MD
- Study on OR2805, a Monoclonal Antibody Targeting CD163, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
- Study on Patient Preference for Subcutaneous vs. Intravenous Pembrolizumab in Various Cancers — Merck Sharp & Dohme LLC
- Study of Pembrolizumab in Children with Advanced Solid Tumors or Lymphoma — Merck Sharp & Dohme LLC
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on Subcutaneous Nivolumab and Relatlimab Combination for Untreated Advanced Melanoma — Bristol-Myers Squibb
- Study on IPN01194 for Adults with Advanced Solid Tumors — Ipsen
- Study on the Safety and Effectiveness of CFT1946 Alone and in Combination for BRAF V600 Mutant Solid Tumors — C4 Therapeutics, Inc.
- Study Comparing ABP 206 and OPDIVO® (Nivolumab) for Patients with Advanced Melanoma — Amgen
- Study to Compare ABP 206 and OPDIVO® (Nivolumab) in Patients with Surgically Removed Melanoma — Amgen
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations — Bristol-Myers Squibb
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma — Regeneron Pharmaceuticals
- Study on Whether Fianlimab and Cemiplimab Work Better Than Pembrolizumab to Prevent Melanoma from Returning After Surgery — Regeneron Pharmaceuticals
- Study on Adjuvant Treatment Based on Response to Pre-Surgery Nivolumab for Melanoma — Abramson Cancer Center at Penn Medicine
- Study on Using Genetically Modified White Blood Cells to Treat Cancers with CD70 Marker — National Cancer Institute (NCI)
- Study on Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab for High-Risk Melanoma — ModernaTX, Inc.
- Study on Anti-PD-1 Antibody with Metabolic Modulator for Treating Solid Tumors — Dan Zandberg
- Study on Axitinib and Ipilimumab for Treating Advanced Melanoma — H. Lee Moffitt Cancer Center and Research Institute
- Study on BI-1808 Alone and with Pembrolizumab for Treating Advanced Cancers — BioInvent International AB
- Study on Brentuximab Vedotin and Pembrolizumab for Treating Metastatic Solid Tumors — Seagen Inc.
- Study on CAB-ROR2-ADC for Treating Advanced Breast, Head & Neck, Lung Cancer, and Melanoma — BioAtla, Inc.
- CD8+ T Cell Imaging During Pre-Surgery Immunotherapy for Melanoma Patients — Memorial Sloan Kettering Cancer Center
- Study on Fianlimab and Cemiplimab Compared to Pembrolizumab for Treating Advanced Melanoma in Adolescents and Adults — Regeneron Pharmaceuticals
- Compassionate Use Program for Trametinib and Dabrafenib in Patients with BRAF Mutation-positive Metastatic Melanoma — Novartis Pharmaceuticals
- Study for Continued Access to Dabrafenib and/or Trametinib Treatment — Novartis Pharmaceuticals
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma — University of Utah
- Study on the Duration of PD-1/PD-L1 Inhibitor Treatment in Advanced Solid Tumors — Jason J. Luke, MD
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Study on GEN1042 Safety and Anti-Tumor Effects in Patients with Advanced Solid Tumors — Genmab
- Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
- Study on Using Sarilumab with Ipilimumab, Nivolumab, and Relatlimab for Advanced Melanoma That Cannot Be Surgically Removed — NYU Langone Health
- Study on IT-hu14.18-IL2 with Radiation, Nivolumab, and Ipilimumab for Advanced Melanoma — University of Wisconsin, Madison
- Study on Neoadjuvant Immunotherapy with Tavo and Electroporation Combined with Nivolumab for Melanoma Patients — H. Lee Moffitt Cancer Center and Research Institute
- Study on Nodal Radiation Therapy for Patients with Sentinel Lymph Node Positive Melanoma — M.D. Anderson Cancer Center
- Study on Pembrolizumab and Lenvatinib for Patients with Brain Metastases from Melanoma or Kidney Cancer — Yale University
- Phase 2 Study of Voyager V1 and Cemiplimab for Cancer Patients — Vyriad, Inc.
- Study on a New Combination Treatment for Metastatic Melanoma (TRINITY) — M.D. Anderson Cancer Center
- Phase II Study of IO102-IO103 and Pembrolizumab (KEYTRUDA®) Before and After Surgery for Patients with Resectable Tumors — IO Biotech
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Effectiveness of OBX-115 for Advanced Solid Tumors — Obsidian Therapeutics, Inc.
- Study on the Safety and Effectiveness of CJRB-101 with Pembrolizumab for Advanced or Metastatic Cancer — CJ Bioscience, Inc.
- Study on Stereotactic Brain Radiation with or without AGuIX Gadolinium-Based Nanoparticles for Brain Metastases — Dana-Farber Cancer Institute
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway — Deciphera Pharmaceuticals, LLC
- Study on EOS-448 with Standard and Experimental Treatments for Advanced Solid Tumors — iTeos Belgium SA
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT for Advanced or Metastatic Cancers — ImaginAb, Inc.
- Study on Lifileucel and Pembrolizumab Combination Compared to Pembrolizumab Alone for Untreated Advanced Melanoma — Iovance Biotherapeutics, Inc.
- Study on the Safety and Effectiveness of Pembrolizumab with Other Treatments or Alone for First-Time Advanced Melanoma — Merck Sharp & Dohme LLC
- Tegavivint for Treating Recurrent or Hard-to-Treat Solid Tumors, Including Lymphomas and Desmoid Tumors — Children's Oncology Group
- Study on the Effects of Sulforaphane from Vegetables in Preventing Melanoma in People with a History of Melanoma — Eastern Cooperative Oncology Group
- Study on Tovorafenib (DAY101) Alone or with Other Treatments for Melanoma and Other Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on Relatlimab, Nivolumab, and Ipilimumab for Patients with Melanoma Brain Metastases — Stanford University
- Study on Zimberelimab and Domvanalimab for Melanoma That Has Not Responded to PD-1 Treatment — Diwakar Davar
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Melanoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.